Now showing items 548-567 of 652

    • Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. 

      Dimopoulos, MA; Palumbo, A; Corradini, P; Cavo, M; Delforge, M; Di Raimondo, F; Weisel, KC; Oriol, A; Hansson, M; Vacca, A; Blanchard, MJ; Goldschmidt, H; Doyen, C; Kaiser, M; Petrini, M; Anttila, P; Cafro, AM; Raymakers, R; San-Miguel, J; de Arriba, F; Knop, S; Röllig, C; Ocio, EM; Morgan, G; Miller, N; Simcock, M; Peluso, T; Herring, J; Sternas, L; Zaki, MH; Moreau, P (2016-07)
      Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients ...
    • Second cancer risk following Hodgkin lymphoma. 

      Sud, A; Hemminki, K; Houlston, RS (2017-10-03)
    • Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. 

      Jones, JR; Cairns, DA; Gregory, WM; Collett, C; Pawlyn, C; Sigsworth, R; Striha, A; Henderson, R; Kaiser, MF; Jenner, M; Cook, G; Russell, NH; Williams, C; Pratt, G; Kishore, B; Lindsay, J; Drayson, MT; Davies, FE; Boyd, KD; Owen, RG; Jackson, GH; Morgan, GJ (2016-12-09)
      We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary ...
    • Second primary cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction. 

      Chattopadhyay, S; Sud, A; Zheng, G; Yu, H; Sundquist, K; Sundquist, J; Försti, A; Houlston, R; Hemminki, A; Hemminki, K (2018-11-15)
      Second primary cancers (SPCs) account for an increasing proportion of all cancer diagnoses. It is unlikely that prior therapy is solely responsible for SPC risk. To investigate risk of SPC after diagnosis of non-Hodgkin ...
    • Second primary cancers in non-Hodgkin lymphoma: Family history and survival. 

      Chattopadhyay, S; Zheng, G; Sud, A; Sundquist, K; Sundquist, J; Försti, A; Houlston, R; Hemminki, A; Hemminki, K (2019-05-04)
      Second primary cancers (SPCs) account for an increasing proportion of all cancer diagnoses and family history of cancer may be a risk factor for SPCs. Using the Swedish Family-Cancer Database on non-Hodgkin lymphoma (NHL), ...
    • Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. 

      Zheng, G; Chattopadhyay, S; Sud, A; Sundquist, K; Sundquist, J; Försti, A; Houlston, R; Hemminki, A; Hemminki, K (2019-04)
      Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi-directional analyses in which relative risks ...
    • Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. 

      Ferraldeschi, R; Welti, J; Powers, MV; Yuan, W; Smyth, T; Seed, G; Riisnaes, R; Hedayat, S; Wang, H; Crespo, M; Nava Rodrigues, D; Figueiredo, I; Miranda, S; Carreira, S; Lyons, JF; Sharp, S; Plymate, SR; Attard, G; Wallis, N; Workman, P; de Bono, JS (2016-05)
      Resistance to available hormone therapies in prostate cancer has been associated with alternative splicing of androgen receptor (AR) and specifically, the expression of truncated and constitutively active AR variant 7 ...
    • Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. 

      Sclafani, F; Chau, I; Cunningham, D; Lampis, A; Hahne, JC; Ghidini, M; Lote, H; Zito, D; Tabernero, J; Glimelius, B; Cervantes, A; Begum, R; De Castro, DG; Wilson, SH; Peckitt, C; Eltahir, Z; Wotherspoon, A; Tait, D; Brown, G; Oates, J; Braconi, C; Valeri, N (2016-09)
      Single nucleotide polymorphisms (SNPs) in microRNA genes have been associated with colorectal cancer (CRC) risk, survival and response to treatment. Conflicting results are available on the association between rs4919510, ...
    • A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. 

      Smyth, EC; Nyamundanda, G; Cunningham, D; Fontana, E; Ragulan, C; Tan, IB; Lin, SJ; Wotherspoon, A; Nankivell, M; Fassan, M; Lampis, A; Hahne, JC; Davies, AR; Lagergren, J; Gossage, JA; Maisey, N; Green, M; Zylstra, JL; Allum, WH; Langley, RE; Tan, P; Valeri, N; Sadanandam, A (2018-12-01)
      Background: Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph node groups there is still heterogeneity with risk ...
    • Shared heritability and functional enrichment across six solid cancers. 

      Jiang, X; Finucane, HK; Schumacher, FR; Schmit, SL; Tyrer, JP; Han, Y; Michailidou, K; Lesseur, C; Kuchenbaecker, KB; Dennis, J; Conti, DV; Casey, G; Gaudet, MM; Huyghe, JR; Albanes, D; Aldrich, MC; Andrew, AS; Andrulis, IL; Anton-Culver, H; Antoniou, AC; Antonenkova, NN; Arnold, SM; Aronson, KJ; Arun, BK; Bandera, EV; Barkardottir, RB; Barnes, DR; Batra, J; Beckmann, MW; Benitez, J; Benlloch, S; Berchuck, A; Berndt, SI; Bickeböller, H; Bien, SA; Blomqvist, C; Boccia, S; Bogdanova, NV; Bojesen, SE; Bolla, MK; Brauch, H; Brenner, H; Brenton, JD; Brook, MN; Brunet, J; Brunnström, H; Buchanan, DD; Burwinkel, B; Butzow, R; Cadoni, G; Caldés, T; Caligo, MA; Campbell, I; Campbell, PT; Cancel-Tassin, G; Cannon-Albright, L; Campa, D; Caporaso, N; Carvalho, AL; Chan, AT; Chang-Claude, J; Chanock, SJ; Chen, C; Christiani, DC; Claes, KBM; Claessens, F; Clements, J; Collée, JM; Correa, MC; Couch, FJ; Cox, A; Cunningham, JM; Cybulski, C; Czene, K; Daly, MB; deFazio, A; Devilee, P; Diez, O; Gago-Dominguez, M; Donovan, JL; Dörk, T; Duell, EJ; Dunning, AM; Dwek, M; Eccles, DM; Edlund, CK; Edwards, DRV; Ellberg, C; Evans, DG; Fasching, PA; Ferris, RL; Liloglou, T; Figueiredo, JC; Fletcher, O; Fortner, RT; Fostira, F; Franceschi, S; Friedman, E; Gallinger, SJ; Ganz, PA; Garber, J; García-Sáenz, JA; Gayther, SA; Giles, GG; Godwin, AK; Goldberg, MS; Goldgar, DE; Goode, EL; Goodman, MT; Goodman, G; Grankvist, K; Greene, MH; Gronberg, H; Gronwald, J; Guénel, P; Håkansson, N; Hall, P; Hamann, U; Hamdy, FC; Hamilton, RJ; Hampe, J; Haugen, A; Heitz, F; Herrero, R; Hillemanns, P; Hoffmeister, M; Høgdall, E; Hong, Y-C; Hopper, JL; Houlston, R; Hulick, PJ; Hunter, DJ; Huntsman, DG; Idos, G; Imyanitov, EN; Ingles, SA; Isaacs, C; Jakubowska, A; James, P; Jenkins, MA; Johansson, M; Johansson, M; John, EM; Joshi, AD; Kaneva, R; Karlan, BY; Kelemen, LE; Kühl, T; Khaw, K-T; Khusnutdinova, E; Kibel, AS; Kiemeney, LA; Kim, J; Kjaer, SK; Knight, JA; Kogevinas, M; Kote-Jarai, Z; Koutros, S; Kristensen, VN; Kupryjanczyk, J; Lacko, M; Lam, S; Lambrechts, D; Landi, MT; Lazarus, P; Le, ND; Lee, E; Lejbkowicz, F; Lenz, H-J; Leslie, G; Lessel, D; Lester, J; Levine, DA; Li, L; Li, CI; Lindblom, A; Lindor, NM; Liu, G; Loupakis, F; Lubiński, J; Maehle, L; Maier, C; Mannermaa, A; Marchand, LL; Margolin, S; May, T; McGuffog, L; Meindl, A; Middha, P; Miller, A; Milne, RL; MacInnis, RJ; Modugno, F; Montagna, M; Moreno, V; Moysich, KB; Mucci, L; Muir, K; Mulligan, AM; Nathanson, KL; Neal, DE; Ness, AR; Neuhausen, SL; Nevanlinna, H; Newcomb, PA; Newcomb, LF; Nielsen, FC; Nikitina-Zake, L; Nordestgaard, BG; Nussbaum, RL; Offit, K; Olah, E; Olama, AAA; Olopade, OI; Olshan, AF; Olsson, H; Osorio, A; Pandha, H; Park, JY; Pashayan, N; Parsons, MT; Pejovic, T; Penney, KL; Peters, WHM; Phelan, CM; Phipps, AI; Plaseska-Karanfilska, D; Pring, M; Prokofyeva, D; Radice, P; Stefansson, K; Ramus, SJ; Raskin, L; Rennert, G; Rennert, HS; van Rensburg, EJ; Riggan, MJ; Risch, HA; Risch, A; Roobol, MJ; Rosenstein, BS; Rossing, MA; De Ruyck, K; Saloustros, E; Sandler, DP; Sawyer, EJ; Schabath, MB; Schleutker, J; Schmidt, MK; Setiawan, VW; Shen, H; Siegel, EM; Sieh, W; Singer, CF; Slattery, ML; Sorensen, KD; Southey, MC; Spurdle, AB; Stanford, JL; Stevens, VL; Stintzing, S; Stone, J; Sundfeldt, K; Sutphen, R; Swerdlow, AJ; Tajara, EH; Tangen, CM; Tardon, A; Taylor, JA; Teare, MD; Teixeira, MR; Terry, MB; Terry, KL; Thibodeau, SN; Thomassen, M; Bjørge, L; Tischkowitz, M; Toland, AE; Torres, D; Townsend, PA; Travis, RC; Tung, N; Tworoger, SS; Ulrich, CM; Usmani, N; Vachon, CM; Van Nieuwenhuysen, E; Vega, A; Aguado-Barrera, ME; Wang, Q; Webb, PM; Weinberg, CR; Weinstein, S; Weissler, MC; Weitzel, JN; West, CML; White, E; Whittemore, AS; Wichmann, H-E; Wiklund, F; Winqvist, R; Wolk, A; Woll, P; Woods, M; Wu, AH; Wu, X; Yannoukakos, D; Zheng, W; Zienolddiny, S; Ziogas, A; Zorn, KK; Lane, JM; Saxena, R; Thomas, D; Hung, RJ; Diergaarde, B; McKay, J; Peters, U; Hsu, L; García-Closas, M; Eeles, RA; Chenevix-Trench, G; Brennan, PJ; Haiman, CA; Simard, J; Easton, DF; Gruber, SB; Pharoah, PDP; Price, AL; Pasaniuc, B; Amos, CI; Kraft, P; Lindström, S (2019-01-25)
      Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total ...
    • SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma. 

      Carreno, G; Boult, JKR; Apps, JR; Gonzalez-Meljem, JM; Haston, S; Guiho, R; Stache, C; Danielson, LS; Koers, A; Smith, LS; Virasami, A; Panousopoulos, L; Buchfelder, M; Jacques, TS; Chesler, L; Robinson, S; Martinez-Barbera, JP (2019-01-01)
      Pharmacological inhibition of the sonic hedgehog (SHH) pathway can be beneficial against certain cancers but detrimental in others. Adamantinomatous craniopharyngioma (ACP) is a relevant pituitary tumour, affecting children ...
    • The shieldin complex mediates 53BP1-dependent DNA repair. 

      Noordermeer, SM; Adam, S; Setiaputra, D; Barazas, M; Pettitt, SJ; Ling, AK; Olivieri, M; Álvarez-Quilón, A; Moatti, N; Zimmermann, M; Annunziato, S; Krastev, DB; Song, F; Brandsma, I; Frankum, J; Brough, R; Sherker, A; Landry, S; Szilard, RK; Munro, MM; McEwan, A; Goullet de Rugy, T; Lin, Z-Y; Hart, T; Moffat, J; Gingras, A-C; Martin, A; van Attikum, H; Jonkers, J; Lord, CJ; Rottenberg, S; Durocher, D (2018-08)
      53BP1 is a chromatin-binding protein that regulates the repair of DNA double-strand breaks by suppressing the nucleolytic resection of DNA termini1,2. This function of 53BP1 requires interactions with PTIP3 and RIF14-9, ...
    • Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. 

      Dowsett, M; Smith, IE; Ebbs, SR; Dixon, JM; Skene, A; Griffith, C; Boeddinghaus, I; Salter, J; Detre, S; Hills, M; Ashley, S; Francis, S; Walsh, G (2005-01)
      PURPOSE: Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of intermediate markers of treatment benefit, thereby circumventing the need for efficacy trials of adjuvant therapy, which require ...
    • Short-term presurgical treatment for all? 

      Dowsett, M; Salter, J; Hills, M; Detre, S; A'Hern, R; Smith, IE (BIOMED CENTRAL LTD, 2007-02)
    • Should tissue structure suppress or amplify selection to minimize cancer risk? 

      Werner, B (2016-08)
      Background: It has been frequently argued that tissues evolved to suppress the accumulation of growth enhancing cancer inducing mutations. A prominent example is the hierarchical structure of tissues with high cell turnover, ...
    • The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma 

      Morgan, G (2014-09)
      Glycosylation is a stepwise procedure of covalent attachment of oligosaccharide chains to proteins or lipids, and alterations in this process, especially increased sialylation, have been associated with malignant transformation ...
    • Signalling pathways implicated in early mammary gland morphogenesis and breast cancer. 

      Howard, B; Ashworth, A (2006-08)
      Specification of mammary epithelial cell fate occurs during embryogenesis as cells aggregate to form the mammary anlage. Within the embryonic mammary bud, a population of epithelial cells exists that will subsequently ...
    • The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia. 

      Dobbins, SE; Sherborne, AL; Ma, YP; Bardini, M; Biondi, A; Cazzaniga, G; Lloyd, A; Chubb, D; Greaves, MF; Houlston, RS (2013-10)
      Over 90% of infants (< 1-year-old) diagnosed with leukemia have pro-B acute lymphoblastic leukemia (ALL) containing the MLL-AF4 fusion. When compared with other forms of paediatric ALL affecting later B-cell differentiation, ...
    • The Silver syndrome variant of hereditary spastic paraplegia maps to chromosome 11q12-q14, with evidence for genetic heterogeneity within this subtype. 

      Patel, H; Hart, PE; Warner, TT; Houlston, RS; Patton, MA; Jeffery, S; Crosby, AH (2001-07)
      The hereditary spastic paraplegias (HSPs) are a complex group of neurodegenerative disorders characterized by lower-limb spasticity and weakness. Silver syndrome (SS) is a particularly disabling dominantly inherited form ...
    • Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer. 

      Heindl, A; Lan, C; Rodrigues, DN; Koelble, K; Yuan, Y (2016-09-19)
      The tumor microenvironment is pivotal in influencing cancer progression and metastasis. Different cells co-exist with high spatial diversity within a patient, yet their combinatorial effects are poorly understood. We ...